Skip to main content
Contact Us
Subscribe
E-Edition
91°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
160.94
-1.60 (-0.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
July 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
July 18, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
June 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
BeiGene, Ltd.
Via
Business Wire
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
May 24, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
May 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in 3/13 Morning Trading
March 13, 2024
Via
Investor Brand Network
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
May 08, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
April 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
April 24, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
April 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
March 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
March 13, 2024
From
BeiGene
Via
Business Wire
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
March 07, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
March 06, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
February 29, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at Upcoming Investor Conferences
February 28, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
February 27, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
February 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
January 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
December 22, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
November 29, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
November 28, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
November 21, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
November 17, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
November 09, 2023
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present at the Jefferies London Healthcare Conference
November 08, 2023
From
BeiGene, Ltd.
Via
Business Wire
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
October 20, 2023
From
BeiGene, Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.